2010•The LancetRequires access

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael J. Hallek, Kirsten Fischer, Guenter R. Fingerle-Rowson, Fink AM, Raimonde Busch, Jiřı́ Mayer, Michelle Hensel, Georg Hopfinger, G Hess, Ulrich von Grünhagen, Michèle Bergmann, J. Catalano, Pier Luigi Zinzani, Federico Caligaris‐Cappio, JF Seymour, Alain J. Berrebi, Ulrich Jäger, Bruno Cazin, Marek Trněný, Anne Westermann, C-M Wendtner, BF Eichhorst, Peter Staib, Andreas Bühler, Dirk F. H. Winkler, Thorsten Zenz, Sebastian Böttcher, Matthias Ritgen, Myriam Mendila, Michael Kneba, Hartmut Döhner, Stefan Stilgenbauer

Open publisher page 1,888 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1888 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Chemoimmunotherapy, Fludarabine, Medicine, Ofatumumab, Rituximab, Cyclophosphamide, Obinutuzumab, Internal medicine